Traduction de «medicine is marketed outside » (Néerlandais → Français) :

If a non-conforming medicine is marketed outside Belgium and the medicine manufacturer is based in Belgium, the FAMHP is responsible for alerting other medicine authorities via the RAS.
If a non-conforming medicine is marketed outside Belgium and the medicine manufacturer is based in Belgium, the FAMHP is responsible for alerting other medicine authorities via the RAS.

Challenging global economic conditions dampened growth in Consumer Health (+1% lc), while Sandoz (+4% lc) achieved greatly improved performances in many key markets outside the US.
Les conditions difficiles de l'économie mondiale ont aussi entravé la croissance de Consumer Health (+1% en m. l.), tandis que Sandoz (+4% en m. l) a grandement amélioré ses performances dans de nombreux marchés-clés en dehors des Etats-Unis.

Diovan (USD 5.7 billion, +10% lc), the world’s top-selling branded medicine for high blood pressure, grew steadily in all key markets worldwide, with areas outside the US now accounting for about 58% of net sales and delivering 10% lc growth.
Diovan (USD 5,7 milliards, +10% en m. l.), médicament numéro un contre l’hypertension dans le monde, a enregistré une croissance régulière dans tous les marchés-clés.

Borderline products and medicines without a market authorisation The trade in traditional medicines such as TCM (Traditional Chinese Medicines, Ayurveda and others) The theft of medicines and their resale on the black market
Borderline products and medicines without a market authorisation The trade in traditional medicines such as TCM (Traditional Chinese Medicines, Ayurveda and others) The theft of medicines and their resale on the black market

In anticipation of changes to the product portfolio in the US, which includes expected approvals for a number of new specialty medicines but also the loss of market exclusivity for Diovan and other medicines in the next few years, Novartis has further streamlined its US business in Pharmaceuticals to maximize the potential of the changing portfolio in both primary care and specialty markets.
Novartis anticipe les changements qui vont intervenir au cours des années à venir dans son portefeuille de produits aux Etats-Unis, notamment les autorisations attendues pour de nouvelles spécialités mais aussi la perte de l’exclusivité du marché pour Diovan et d’autres médicaments. C’est ainsi que Pharmaceuticals a encore rationalisé ses opérations américaines pour maximiser le potentiel d’un portefeuille en plein changement, à la fois dans les soins de santé primaires et dans les marchés des spécialités.

The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.
The latter has been designated as having expertise as an “Official Medicines Control Laboratory”, recognised by the FAMHP and the European Directorate for the Quality of Medicines (EDQM), for the monitoring of immunological products for veterinary use prior to marketing authorisation for the Belgian market.

The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.
The Registration (marketing authorisation) department of the FAMHP is responsible for evaluating new applications and applications for changes to existing marketing authorisations (variations), with a view to grant the authorisation for marketing a medicine or health product.

The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.
The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.
Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.